We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Hyperactive dealmaking

8 May 2018 By Neil Unmack

The Japanese drugmaker finally reached a deal to buy its Irish peer, for $62 bln. Takeda can just about make the deal math work with $1.4 bln of annual cost savings. It requires big cuts to R&D, however, and operating with excessive debt for a while. That’s a dangerous mix.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)